Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

Bibliography

• Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87
   PubMed Web of Science ®Google Scholar
• Zhao G, Dharmadhikari G, Maedler K, et al. Possible role of interleukin-1beta in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. PLoS Comput Biol 2014;10:e1003798
   PubMedGoogle Scholar
• Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014;40:176-85
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068-83
   PubMed Web of Science ®Google Scholar
• Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Rev Immunol 2011;11:98-107
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T. Type 2 diabetes mellitus: a metabolic autoinflammatory disease. Dermatol Clin 2013;31:495-506
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141-50
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38
   PubMed Web of Science ®Google Scholar
• Pateras I, Giaginis C, Tsigris C, et al. NF-kappaB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Exp Opin Ther Targets 2014;18:1089-101
   PubMed Web of Science ®Google Scholar
• Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014;35:578-89
   PubMed Web of Science ®Google Scholar
• Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009;116:219-30
   PubMed Web of Science ®Google Scholar
• Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998;182:169-75
   PubMed Web of Science ®Google Scholar
• Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-17
   PubMed Web of Science ®Google Scholar
• Ursini F, Naty S, Grembiale RD. Infliximab and insulin resistance. Autoimmun Rev 2010;9:536-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010;1193:153-9
   PubMed Web of Science ®Google Scholar
• Esser N, L’Homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487-97
   PubMed Web of Science ®Google Scholar
• Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 2013;4:50
   Google Scholar
• Donath MY, Dalmas E, Sauter NS, et al. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab 2013;17:860-72
   PubMed Web of Science ®Google Scholar
• Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol 2013;147:242-75
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014;13:465-76
   PubMed Web of Science ®Google Scholar
• Boni-Schnetzler M, Donath MY. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br J Clin Pharmacol 2013;76:263-8
   PubMed Web of Science ®Google Scholar
• Imai Y, Dobrian AD, Weaver JR, et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab 2013;15 Suppl 3:117-29
   PubMed Web of Science ®Google Scholar
• Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs 2013;18:193-205
   PubMed Web of Science ®Google Scholar
• Golia E, Limongelli G, Natale F, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep 2014;16:435
   PubMed Web of Science ®Google Scholar
• Deans KA, Sattar N. "Anti-inflammatory" drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006;8:18-27
   PubMed Web of Science ®Google Scholar
• Esser N, Paquot N, Scheen AJ. Diabète de type 2 et médicaments anti-inflammatoires : nouvelles perspectives thérapeutiques ? Rev Med Suisse 2011;7:1614-18, 20
   PubMedGoogle Scholar
• Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339:166-72
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes. Diabetes Obes Metab 2013;15(Suppl 3):193-6
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, et al. Novel directions for diabetes mellitus drug discovery. Exp Opin Drug Discov 2013;8:35-48
   PubMed Web of Science ®Google Scholar
• Awan Z, Genest J. Inflammation modulation and cardiovascular disease prevention. Eur J Prev Cardiol 2014;10.1177/2047487314529350
   Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10
   PubMed Web of Science ®Google Scholar
• Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009;2:34-40
   PubMedGoogle Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70
   PubMed Web of Science ®Google Scholar
• Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207. e15
   PubMed Web of Science ®Google Scholar
• White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11
   PubMed Web of Science ®Google Scholar
• Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother 2010;44:1207-21
   PubMed Web of Science ®Google Scholar
• Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998;396:77-80
   PubMed Web of Science ®Google Scholar
• Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-7
   PubMed Web of Science ®Google Scholar
• Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6
   PubMed Web of Science ®Google Scholar
• Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358-63
   PubMed Web of Science ®Google Scholar
• Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62:2164-72
   PubMed Web of Science ®Google Scholar
• Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol Metab 2013;24:481-7
   PubMed Web of Science ®Google Scholar
• Fleischman A, Shoelson SE, Bernier R, et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-94
   PubMed Web of Science ®Google Scholar
• Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009;52:385-93
   PubMed Web of Science ®Google Scholar
• Faghihimani E, Aminorroaya A, Rezvanian H, et al. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract 2012;18:826-33
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013;56:714-23
   PubMed Web of Science ®Google Scholar
• Kim SH, Liu A, Ariel D, et al. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. Diabetes Care 2014;37:1944-50
   PubMed Web of Science ®Google Scholar
• Fakhri M, Imani EF, Khalili N. The effect of salsalate on biochemical factors and endothelial dysfunction of prediabetic patients: a randomized clinical trial. J Res Med Sci 2014;19:287-92
   Web of Science ®Google Scholar
• Nohria A, Kinlay S, Buck JS, et al. The effect of salsalate therapy on endothelial function in a broad range of subjects. J Am Heart Assoc 2014;3:e000609
   Google Scholar
• Faghihimani E, Amini M, Adibi A, et al. Evaluating the efficacy of Salsalate on prediabetic and diabetic patients with fatty liver: a randomized clinical trial. J Res Pharm Pract 2013;2:40-3
   Google Scholar
• Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008;1:36-43
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010;152:346-57
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013;159:1-12
   Google Scholar
• Barzilay JI, Jablonski KA, Fonseca V, et al. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care 2014;37:1083-91
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Buck JS, Desouza C, et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care 2013;36:4132-9
   PubMed Web of Science ®Google Scholar
• Faghihimani E, Aminorroaya A, Rezvanian H, et al. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2013;50:537-43
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-801
   PubMed Web of Science ®Google Scholar
• Ibfelt T, Fischer CP, Plomgaard P, et al. The acute effects of low-dose TNF-alpha on glucose metabolism and beta-cell function in humans. Mediators Inflamm 2014;2014:295478
   PubMed Web of Science ®Google Scholar
• Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009;22:61-73
   PubMed Web of Science ®Google Scholar
• Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn’s disease. Inflamm Bowel Dis 2009;15:1476-84
   PubMed Web of Science ®Google Scholar
• Paquot N, Castillo MJ, Lefebvre PJ, et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-19
   PubMed Web of Science ®Google Scholar
• Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006;166:902-8
   PubMed Web of Science ®Google Scholar
• Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011;96:E146-50
   PubMed Web of Science ®Google Scholar
• Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5
   PubMed Web of Science ®Google Scholar
• Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25
   PubMed Web of Science ®Google Scholar
• Lo J, Bernstein LE, Canavan B, et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007;293:E102-9
   PubMed Web of Science ®Google Scholar
• Popa C, Netea MG, van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-62
   PubMed Web of Science ®Google Scholar
• Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008;9:1121-8
   PubMed Web of Science ®Google Scholar
• Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004;34:641-2
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6
   PubMed Web of Science ®Google Scholar
• Huvers FC, Popa C, Netea MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007;66:558-9
   PubMed Web of Science ®Google Scholar
• Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8
   PubMed Web of Science ®Google Scholar
• Rosenvinge A, Krogh-Madsen R, Baslund B, et al. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007;36:91-6
   PubMed Web of Science ®Google Scholar
• Seriolo B, Paolino S, Ferrone C, et al. Impact of long-term anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:159-60. author reply 60
   PubMed Web of Science ®Google Scholar
• Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012;14:R141
   PubMed Web of Science ®Google Scholar
• Miranda-Filloy JA, Llorca J, Carnero-Lopez B, et al. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:850-5
   PubMed Web of Science ®Google Scholar
• Ferraz-Amaro I, Arce-Franco M, Muniz J, et al. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res 2011;43:801-8
   PubMed Web of Science ®Google Scholar
• Cuchacovich R, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? Clin Rheumatol 2009;28:1217-20
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2013;33:833-9
   Web of Science ®Google Scholar
• Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525-31
   PubMed Web of Science ®Google Scholar
• Antohe JL, Bili A, Sartorius JA, et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 2012;64:215-21
   PubMed Web of Science ®Google Scholar
• Cugno M, Ingegnoli F, Gualtierotti R, et al. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 2010;8:285-92
   PubMed Web of Science ®Google Scholar
• Foster W, Carruthers D, Lip GY, et al. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J Rheumatol 2010;37:711-16
   PubMed Web of Science ®Google Scholar
• Sandoo A, Kitas GD, Carroll D, et al. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther 2012;14:R117
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
   PubMed Web of Science ®Google Scholar
• Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta 2012;413:1163-70
   PubMed Web of Science ®Google Scholar
• Besedovsky HO, Rey AD. Physiologic versus diabetogenic effects of interleukin-1: a question of weight. Curr Pharm Des 2014;20:4733-40
   PubMed Web of Science ®Google Scholar
• Speaker KJ, Fleshner M. Interleukin-1 beta: a potential link between stress and the development of visceral obesity. BMC Physiol 2012;12:8
   PubMedGoogle Scholar
• Dinarello CA. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. Int J Tissue React 1992;14:65-75
   PubMedGoogle Scholar
• Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:314-21
   PubMed Web of Science ®Google Scholar
• Tack CJ, Stienstra R, Joosten LA, et al. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 2012;249:239-52
   PubMed Web of Science ®Google Scholar
• Stienstra R, Tack CJ, Kanneganti TD, et al. The inflammasome puts obesity in the danger zone. Cell Metab 2012;15:10-18
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52
   PubMed Web of Science ®Google Scholar
• Maedler K, Dharmadhikari G, Schumann DM, et al. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol 2011(203):257-78
   PubMedGoogle Scholar
• Rydgren T, Oster E, Sandberg M, et al. Administration of IL-1 trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice. Cytokine 2013;63:123-9
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta. J Mol Biol 2013;425:94-111
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009(1):CD005121
   Google Scholar
• Vitale A, Cantarini L, Rigante D, et al. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol 2014;published on line 2014;10.1007/s10067-014-2601-7
   Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-8
   PubMed Web of Science ®Google Scholar
• van Asseldonk EJ, Stienstra R, Koenen TB, et al. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011;96:2119-26
   PubMed Web of Science ®Google Scholar
• van Poppel PC, van Asseldonk EJ, Holst JJ, et al. The interleukin-1 receptor antagonist anakinra improves first phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab 2014;published on line 2014;10.1111/dom.12357
   Google Scholar
• Palmer R, Nyman E, Penney M, et al. Effects of IL-1beta-blocking therapies in type 2 diabetes mellitus: a quantitative systems Ppharmacology modeling approach to explore underlying mechanisms. CPT Pharmacometrics Syst Pharmacol 2014;3:e118
   Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012;51:e1-18
   PubMedGoogle Scholar
• Rissanen A, Howard CP, Botha J, et al. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012;14:1088-96
   PubMed Web of Science ®Google Scholar
• Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739-48
   PubMed Web of Science ®Google Scholar
• Hensen J, Howard CP, Walter V, et al. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab 2013;39:524-31
   PubMed Web of Science ®Google Scholar
• Noe A, Howard C, Thuren T, et al. Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus. Clin Ther 2014;10.1016/j.clinthera.2014.08.004
   PubMed Web of Science ®Google Scholar
• Howard C, Noe A, Skerjanec A, et al. Safety and tolerability of canakinumab, an IL-1beta inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 2014;13:94
   PubMed Web of Science ®Google Scholar
• Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605
   PubMed Web of Science ®Google Scholar
• McCarty S, Frishman W. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease. Cardiol Rev 2014;22:176-8
   PubMed Web of Science ®Google Scholar
• Issafras H, Corbin JA, Goldfine ID, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1 beta antibody with differential receptor-modulating properties. J Pharmacol Exp Ther 2014;348:202-15
   PubMed Web of Science ®Google Scholar
• Handa M, Vanegas S, Maddux BA, et al. XOMA 052, an anti-IL-1beta monoclonal antibody, prevents IL-1beta-mediated insulin resistance in 3T3-L1 adipocytes. Obesity (Silver Spring) 2013;21:306-9
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35:1654-62
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Furrer R, Keller C, et al. Inhibition of IL-1beta improves fatigue in type 2 diabetes. Diabetes Care 2011;34:e158
   PubMed Web of Science ®Google Scholar
• Geiler J, McDermott MF. Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther 2010;12:755-69
   PubMed Web of Science ®Google Scholar
• Roubille F, Busseuil D, Shi Y, et al. The interleukin-1beta modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis 2014;236:277-85
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N, Maltezos E. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? Expert Opin Investig Drugs 2014;23:1277-84
   PubMed Web of Science ®Google Scholar
• Bihorel S, Fiedler-Kelly J, Ludwig E, et al. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J 2014;16:1009-17
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 2013;36:2239-46
   PubMed Web of Science ®Google Scholar
• Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol 2014;92:331-9
   PubMed Web of Science ®Google Scholar
• Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-13
   PubMed Web of Science ®Google Scholar
• Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2014;63:1115-23
   PubMed Web of Science ®Google Scholar
• Qu D, Liu J, Lau CW, et al. Interleukin-6 in diabetes and cardiovascular complications. Br J Pharmacol 2014;171:3595-603
   PubMed Web of Science ®Google Scholar
• Kraakman MJ, Allen TL, Whitham M, et al. Targeting gp130 to prevent inflammation and promote insulin action. Diabetes Obes Metab 2013;15(Suppl 3):170-5
   PubMedGoogle Scholar
• Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379:1214-24
   PubMed Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83
   PubMed Web of Science ®Google Scholar
• Mirjafari H, Ruperto N, Brunner HI, et al. A54: insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. Arthritis Rheumatol 2014;66(Suppl 11):S80-1
   Google Scholar
• Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010;5:e14328
   PubMed Web of Science ®Google Scholar
• Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody. tocilizumab. Ann Rheum Dis 2011;70:1164-5
   PubMed Web of Science ®Google Scholar
• Harder-Lauridsen NM, Krogh-Madsen R, Holst JJ, et al. Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2014;306:E769-78
   PubMed Web of Science ®Google Scholar
• Li L, Wu LL. Adiponectin and interleukin-6 in inflammation-associated disease. Vitam Horm 2012;90:375-95
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Zampeli E, Fragiadaki K, et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011;219:734-6
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Carling D, Prentki M, et al. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123:2764-72
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 2011;131:242-53
   PubMed Web of Science ®Google Scholar
• Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-22
   PubMed Web of Science ®Google Scholar
• Coughlan KA, Valentine RJ, Ruderman NB, et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 2014;7:241-53
   PubMedGoogle Scholar
• Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 2012;21:1155-67
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Karis D. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Exp Opin Ther Patents 2012;22:1467-77
   PubMed Web of Science ®Google Scholar
• Anil TM, Harish C, Lakshmi MN, et al. CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models. Cardiovasc Diabetol 2014;13:27
   PubMedGoogle Scholar
• Zhang LN, Xu L, Zhou HY, et al. Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One 2013;8:e72092
   PubMedGoogle Scholar
• Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013;25:1939-48
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Xu XJ, Nelson L, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 2010;298:E751-60
   PubMed Web of Science ®Google Scholar
• Song YS, Lee SK, Jang YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract 2013;101:341-8
   PubMed Web of Science ®Google Scholar
• Gillum MP, Kotas ME, Erion DM, et al. SirT1 regulates adipose tissue inflammation. Diabetes 2011;60:3235-45
   PubMed Web of Science ®Google Scholar
• Kotas ME, Gorecki MC, Gillum MP. Sirtuin-1 is a nutrient-dependent modulator of inflammation. Adipocyte 2013;2:113-18
   PubMedGoogle Scholar
• Huynh FK, Hershberger KA, Hirschey MD. Targeting sirtuins for the treatment of diabetes. Diabetes Manag (Lond) 2013;3:245-57
   Google Scholar
• Kitada M, Kume S, Kanasaki K, et al. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013;14:622-36
   PubMed Web of Science ®Google Scholar
• Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554-63
   PubMed Web of Science ®Google Scholar
• Guo R, Liu B, Wang K, et al. Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-kappaB pathway. Diab Vasc Dis Res 2014;11:92-102
   PubMed Web of Science ®Google Scholar
• Goh KP, Lee HY, Lau DP, et al. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab 2014;24:2-13
   PubMed Web of Science ®Google Scholar
• Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 2013;1290:83-9
   PubMed Web of Science ®Google Scholar
• Liu K, Zhou R, Wang B, et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2014;99:1510-19
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma W, Zhang P, et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2014;10.1016/j.clnu.2014.03.009
   Web of Science ®Google Scholar
• Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA internal medicine 2014;174:1077-84
   PubMed Web of Science ®Google Scholar
• Pollack RM, Crandall JP. Resveratrol: therapeutic potential for improving cardiometabolic health. Am J Hypertens 2013;26:1260-8
   PubMed Web of Science ®Google Scholar
• Hubbard BP, Gomes AP, Dai H, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013;339:1216-19
   PubMed Web of Science ®Google Scholar
• Sinclair DA, Guarente L. Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 2014;54:363-80
   PubMed Web of Science ®Google Scholar
• Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-16
   PubMed Web of Science ®Google Scholar
• Yoshizaki T, Schenk S, Imamura T, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 2010;298:E419-28
   PubMed Web of Science ®Google Scholar
• Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012;7:e51395
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian S, Noh RM, Daga S, et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J AmHeart Assoc 2013;2:e000042
   PubMed Web of Science ®Google Scholar
• Baksi A, Kraydashenko O, Zalevkaya A, et al. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol 2014;78:69-77
   PubMed Web of Science ®Google Scholar
• Maya-Monteiro CM, Bozza PT. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle 2008;7:1713-17
   PubMed Web of Science ®Google Scholar
• Tarantino G, Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med 2013;45:348-56
   PubMed Web of Science ®Google Scholar
• Martinet W, De Loof H, De Meyer GR. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 2014;233:601-7
   PubMed Web of Science ®Google Scholar
• Jia L, Hui RT. Everolimus, a promising medical therapy for coronary heart disease? Med Hypotheses 2009;73:153-5
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-24
   PubMed Web of Science ®Google Scholar
• Kang YS, Cha JJ, Hyun YY, et al. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments. Expert Opin Investig Drugs 2011;20:745-56
   PubMed Web of Science ®Google Scholar
• Sullivan TJ, Miao Z, Zhao BN, et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 2013;62:1623-32
   PubMed Web of Science ®Google Scholar
• Sullivan T, Miao Z, Dairaghi DJ, et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 2013;305:F1288-97
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Schell E, Gouni-Berthold I, et al. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. J Diabetes Metab 2012;3:1-8
   Google Scholar
• Di Prospero NA, Artis E, Andrade-Gordon P, et al. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes Metab 2014;16:1055-64
   PubMed Web of Science ®Google Scholar
• Hirabara SM, Gorjao R, Vinolo MA, et al. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012;2012:379024
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-97
   PubMed Web of Science ®Google Scholar
• Dalmas E, Venteclef N, Caer C, et al. T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 2014;63:1966-77
   PubMed Web of Science ®Google Scholar